{"id":"cefamandole","rwe":[{"pmid":"41272089","year":"2025","title":"Repurposing cephalosporins as excellent anticancer agents and chemosensitizers for inflammation-driven cancer therapy.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"41259247","year":"2025","title":"Compatibility and stability of seven selected cephalosporin antibiotics during extended infusion.","finding":"","journal":"Science progress","studyType":"Clinical Study"},{"pmid":"41067790","year":"2025","title":"Drug-induced immune haemolytic anaemia caused by cefamandole sodium: Complete serologic studies and clinical follow-up.","finding":"","journal":"Transfusion medicine (Oxford, England)","studyType":"Clinical Study"},{"pmid":"39947613","year":"2025","title":"Analysis of two Nocardia brasiliensis class A β-lactamases (BRA-1 and BRS-1) and related resistance to β-lactam antibiotics.","finding":"","journal":"Journal of global antimicrobial resistance","studyType":"Clinical Study"},{"pmid":"39315412","year":"2024","title":"Research on Drug Efficacy using a Terahertz Metasurface Microfluidic Biosensor Based on Fano Resonance Effect.","finding":"","journal":"ACS applied materials & interfaces","studyType":"Clinical Study"}],"tags":[{"label":"cefamandole","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Solute carrier family 15 member 1","category":"target"},{"label":"SLC15A1","category":"gene"},{"label":"J01DC03","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Bacterial infection due to Klebsiella pneumoniae","category":"indication"},{"label":"Bacterial peritonitis","category":"indication"},{"label":"Bacterial septicemia","category":"indication"},{"label":"Bacterial urinary infection","category":"indication"},{"label":"E. Coli Peritonitis","category":"indication"},{"label":"Enterococcus Urinary Tract Infection","category":"indication"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"contraindications":["Alcoholism","Blood coagulation disorder","Factor II deficiency","Kidney disease","Pseudomembranous enterocolitis"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cefadole","offLabel":[],"synonyms":["cefamandole","cefadole","cefamandol","cephadole","cephamandole"],"timeline":[{"date":"1985-09-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Cefadole (Cefamandole) is a small molecule antibiotic in the cefamandole class, targeting the solute carrier family 15 member 1. It is used to treat various bacterial infections, including those caused by Klebsiella pneumoniae, E. coli, and Enterococcus. Cefadole is off-patent and available as a generic medication. Its commercial status is generic, with one generic manufacturer listed. Key safety considerations include its short half-life of 0.75 hours and high bioavailability of 96%.","brandName":"Cefadole","ecosystem":[{"indication":"Bacterial infection due to Klebsiella pneumoniae","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Bacterial peritonitis","otherDrugs":[{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"cefepime","slug":"cefepime","company":"Hospira Inc"},{"name":"ceftizoxime","slug":"ceftizoxime","company":""}],"globalPrevalence":null},{"indication":"Bacterial septicemia","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"}],"globalPrevalence":null},{"indication":"Bacterial urinary infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"avibactam","slug":"avibactam","company":"Cerexa Inc"}],"globalPrevalence":null},{"indication":"E. Coli Peritonitis","otherDrugs":[{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"cefotaxime","slug":"cefotaxime","company":"Sanofi Aventis Us"},{"name":"cefotetan","slug":"cefotetan","company":""}],"globalPrevalence":null},{"indication":"Enterococcus Urinary Tract Infection","otherDrugs":[{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"carbenicillin","slug":"carbenicillin","company":"Roerig"},{"name":"cefotaxime","slug":"cefotaxime","company":"Sanofi Aventis Us"},{"name":"cefradine","slug":"cefradine","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Escherichia coli urinary tract infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"betaine","slug":"betaine","company":"Rare Dis Therap"}],"globalPrevalence":null},{"indication":"Haemophilus Septicemia","otherDrugs":[{"name":"ceftazidime","slug":"ceftazidime","company":"Covis Injectables"},{"name":"ceftriaxone","slug":"ceftriaxone","company":""},{"name":"cefuroxime","slug":"cefuroxime","company":"Covis Injectables"}],"globalPrevalence":null}],"mechanism":{"target":"Solute carrier family 15 member 1","targets":[{"gene":"SLC15A1","source":"DrugCentral","target":"Solute carrier family 15 member 1","protein":"Solute carrier family 15 member 1"}],"modality":"Small Molecule","drugClass":"cefamandole","explanation":"Imagine your body's cells are like buildings, and bacteria are like construction workers. Cefadole stops the bacteria from building their cell walls, which are essential for their survival. Without these walls, the bacteria can't function and eventually die.","oneSentence":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Cefadole exerts its antibacterial effect by inhibiting the action of penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. This results in the disruption of the bacterial cell wall, ultimately leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/527","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEFAMANDOLE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFAMANDOLE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:15:15.897610","biosimilars":[],"competitors":[{"drugName":"cefoxitin","drugSlug":"cefoxitin","fdaApproval":"1978-10-18","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefuroxime","drugSlug":"cefuroxime","fdaApproval":"1983-10-19","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefaclor","drugSlug":"cefaclor","fdaApproval":"1979-04-04","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefotetan","drugSlug":"cefotetan","fdaApproval":"1985-12-27","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefonicid","drugSlug":"cefonicid","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefotiam","drugSlug":"cefotiam","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"loracarbef","drugSlug":"loracarbef","fdaApproval":"1991-12-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefmetazole","drugSlug":"cefmetazole","fdaApproval":"1989-12-11","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefprozil","drugSlug":"cefprozil","fdaApproval":"1991-12-23","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceforanide","drugSlug":"ceforanide","fdaApproval":"1984-05-24","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"cefamandole","indications":{"approved":[{"name":"Bacterial infection due to Klebsiella pneumoniae","source":"DrugCentral","snomedId":186435004,"regulator":"FDA"},{"name":"Bacterial peritonitis","source":"DrugCentral","snomedId":197171003,"regulator":"FDA"},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA"},{"name":"Bacterial urinary infection","source":"DrugCentral","snomedId":312124009,"regulator":"FDA"},{"name":"E. Coli Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterococcus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Escherichia coli urinary tract infection","source":"DrugCentral","snomedId":301011002,"regulator":"FDA"},{"name":"Haemophilus Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus influenzae pneumonia","source":"DrugCentral","snomedId":70036007,"regulator":"FDA"},{"name":"Infection due to Enterobacteriaceae","source":"DrugCentral","snomedId":128945009,"regulator":"FDA"},{"name":"Infection due to Escherichia coli","source":"DrugCentral","snomedId":71057007,"regulator":"FDA"},{"name":"Infection due to Staphylococcus aureus","source":"DrugCentral","snomedId":406602003,"regulator":"FDA"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Infectious disease of abdomen","source":"DrugCentral","snomedId":128070006,"regulator":"FDA"},{"name":"Infectious disorder of joint","source":"DrugCentral","snomedId":363162000,"regulator":"FDA"},{"name":"Klebsiella cystitis","source":"DrugCentral","snomedId":60867007,"regulator":"FDA"},{"name":"Lower respiratory tract infection","source":"DrugCentral","snomedId":50417007,"regulator":"FDA"},{"name":"Osteomyelitis due to Staphylococcus aureus","source":"DrugCentral","snomedId":428783003,"regulator":"FDA"},{"name":"Peritonitis","source":"DrugCentral","snomedId":48661000,"regulator":"FDA"},{"name":"Pneumonia","source":"DrugCentral","snomedId":233604007,"regulator":"FDA"},{"name":"Pneumonia due to Escherichia coli","source":"DrugCentral","snomedId":51530003,"regulator":"FDA"},{"name":"Pneumonia due to Streptococcus","source":"DrugCentral","snomedId":34020007,"regulator":"FDA"},{"name":"Prevention of Perioperative Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Proteus pneumonia","source":"DrugCentral","snomedId":195888009,"regulator":"FDA"},{"name":"Proteus urinary tract infection","source":"DrugCentral","snomedId":301012009,"regulator":"FDA"},{"name":"Septicemia due to Escherichia coli","source":"DrugCentral","snomedId":9323009,"regulator":"FDA"},{"name":"Skin and Skin Structure Proteus Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":251400000,"prevalenceMethod":"curated","prevalenceSource":"Pathogens, 2024 (PMID:39452777)"},{"name":"Staphylococcal pneumonia","source":"DrugCentral","snomedId":22754005,"regulator":"FDA"},{"name":"Staphylococcal septicemia","source":"DrugCentral","snomedId":111821004,"regulator":"FDA"},{"name":"Staphylococcus Aureus Joint Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staphylococcus Epidermidis Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcal septicemia","source":"DrugCentral","snomedId":29577008,"regulator":"FDA"},{"name":"Streptococcus pyogenes infection","source":"DrugCentral","snomedId":302809008,"regulator":"FDA"},{"name":"Urinary tract infectious disease","source":"DrugCentral","snomedId":68566005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cefoxitin","brandName":"cefoxitin","genericName":"cefoxitin","approvalYear":"1978","relationship":"same-class"},{"drugId":"cefuroxime","brandName":"cefuroxime","genericName":"cefuroxime","approvalYear":"1983","relationship":"same-class"},{"drugId":"cefaclor","brandName":"cefaclor","genericName":"cefaclor","approvalYear":"1979","relationship":"same-class"},{"drugId":"cefotetan","brandName":"cefotetan","genericName":"cefotetan","approvalYear":"1985","relationship":"same-class"},{"drugId":"cefonicid","brandName":"cefonicid","genericName":"cefonicid","approvalYear":"","relationship":"same-class"},{"drugId":"cefotiam","brandName":"cefotiam","genericName":"cefotiam","approvalYear":"","relationship":"same-class"},{"drugId":"loracarbef","brandName":"loracarbef","genericName":"loracarbef","approvalYear":"1991","relationship":"same-class"},{"drugId":"cefmetazole","brandName":"cefmetazole","genericName":"cefmetazole","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefprozil","brandName":"cefprozil","genericName":"cefprozil","approvalYear":"1991","relationship":"same-class"},{"drugId":"ceforanide","brandName":"ceforanide","genericName":"ceforanide","approvalYear":"1984","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05654090","phase":"PHASE4","title":"Evaluate Bioequivalence of Burotam (1/1 g/Vial)","status":"UNKNOWN","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2022-08-25","conditions":["Infectious Diseases"],"enrollment":14,"completionDate":"2023-02-20"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT01601093","phase":"PHASE2","title":"Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","status":"SUSPENDED","sponsor":"Xiangbei Welman Pharmaceutical Co., Ltd","startDate":"2011-11","conditions":["Respiratory Tract Infections","Urinary Tract Infections"],"enrollment":288,"completionDate":"2022-12-15"},{"nctId":"NCT03436719","phase":"NA","title":"Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.","status":"UNKNOWN","sponsor":"State Scientific Centre of Coloproctology, Russian Federation","startDate":"2017-11-06","conditions":["Rectal Cancer"],"enrollment":280,"completionDate":"2020-08-31"},{"nctId":"NCT02775968","phase":"","title":"Population Pharmacokinetics of Cephalosporins and Macrolides in Chinese Children With Community Acquired Pneumonia","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2017-06-21","conditions":["Community Acquired Pneumonia"],"enrollment":750,"completionDate":"2022-10"},{"nctId":"NCT02060149","phase":"PHASE1,PHASE2","title":"The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2014-03","conditions":["Pneumonia"],"enrollment":90,"completionDate":"2015-04"},{"nctId":"NCT01992198","phase":"PHASE4","title":"Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis","status":"UNKNOWN","sponsor":"Erzhen Chen","startDate":"2012-07","conditions":["Pancreatitis,Acute Necrotizing"],"enrollment":60,"completionDate":"2016-12"},{"nctId":"NCT00360607","phase":"PHASE4","title":"A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":["Infection"],"enrollment":307,"completionDate":"2005-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000147750","MMSL":"d00062","NDDF":"004844","UNII":"5CKP8C2LLI","VUID":"4019658","CHEBI":"CHEBI:3480","VANDF":"4019658","INN_ID":"3329","RXNORM":"2178","UMLSCUI":"C0007541","ChEMBL_ID":"CHEMBL1146","KEGG_DRUG":"D02344","DRUGBANK_ID":"DB01326","PDB_CHEM_ID":"SMX","PUBCHEM_CID":"456255","SNOMEDCT_US":"372801003","IUPHAR_LIGAND_ID":"12210","MESH_DESCRIPTOR_UI":"D002435"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.75 hours","clearance":"3.6 mL/min/kg","bioavailability":"96%","fractionUnbound":"0.25%","volumeOfDistribution":"0.16 L/kg"},"publicationCount":1348,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DC03","allCodes":["J01DC03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 21","pmid":"41272089","title":"Repurposing cephalosporins as excellent anticancer agents and chemosensitizers for inflammation-driven cancer therapy.","journal":"Scientific reports"},{"date":"2025 Oct-Dec","pmid":"41259247","title":"Compatibility and stability of seven selected cephalosporin antibiotics during extended infusion.","journal":"Science progress"},{"date":"2025 Oct 9","pmid":"41067790","title":"Drug-induced immune haemolytic anaemia caused by cefamandole sodium: Complete serologic studies and clinical follow-up.","journal":"Transfusion medicine (Oxford, England)"},{"date":"2025 May","pmid":"39947613","title":"Analysis of two Nocardia brasiliensis class A β-lactamases (BRA-1 and BRS-1) and related resistance to β-lactam antibiotics.","journal":"Journal of global antimicrobial resistance"},{"date":"2024 Oct 2","pmid":"39315412","title":"Research on Drug Efficacy using a Terahertz Metasurface Microfluidic Biosensor Based on Fano Resonance Effect.","journal":"ACS applied materials & interfaces"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Lilly"],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}